Embecta Corp EMBC
Recurring cash flows from established chronic-care injection channels, durable while patients and providers continue to value reliable, low-cost delivery over novel alternatives.
Management holds this up; Risk is the soft spot.
| Moat | 3.0 |
| Management | 8.0 |
| Valuation | 7.0 |
| Risk · 10 = lowest | 3.0 |
| Business model | 5.0 |
| Optionality | 5.0 |
The price needs 0.0% growth a year for ten years. The AI thinks 4.0% is achievable, at a 18.0% margin.
The +4.0% gap (4% achievable vs 0% required at 18% margin) indicates the stock is undervalued, as it can deliver growth well above the level needed to justify the current price under the FCF approach.
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.
Start the thirty days · no card